After a disappointing Q2 (-4% CER sales growth), Roche had some respite in Q3 (+1%) – though below expectations, largely driven by diagnostics due to the strong demand for COVID-19 tests. While the older oncology drugs continued facing pressure, newer drugs did better.
Management maintained its 2020 guidance and committed to higher dividends. While the on-going pharma transition may cap near-term sales, an adequate cushion should emanate via diagnostics. Moreover, investments in newer (high-pot ....
16 Oct 2020
Some Q3 recovery (vs. Q2); full-year guidance reiterated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Some Q3 recovery (vs. Q2); full-year guidance reiterated
- Published:
16 Oct 2020 -
Author:
Surbhit Gupta -
Pages:
6
After a disappointing Q2 (-4% CER sales growth), Roche had some respite in Q3 (+1%) – though below expectations, largely driven by diagnostics due to the strong demand for COVID-19 tests. While the older oncology drugs continued facing pressure, newer drugs did better.
Management maintained its 2020 guidance and committed to higher dividends. While the on-going pharma transition may cap near-term sales, an adequate cushion should emanate via diagnostics. Moreover, investments in newer (high-pot ....